#United States #New York #Class Action #Gross Law Firm #Regeneron Pharmaceuticals

Regulatory News: Regeneron Pharmaceuticals Investors Alert

On March 10, 2025, The Gross Law Firm announced an important notice targeted at shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). As part of this notification, shareholders who purchased stocks during a specific class period are encouraged to reach out to the firm for potential lead plaintiff appointment amid the unfolding class action lawsuit.

What You Need to Know

Class Period Details

The class period for this lawsuit extends from November 2, 2023, to October 30, 2024. During this timeframe, several allegations have surfaced against Regeneron that could significantly impact its investors.

Allegations Against Regeneron

The lawsuit alleges that Regeneron made materially false and misleading statements regarding its business practices. Key points of concern include:
1. Payment of Credit Card Fees: It is claimed that Regeneron paid credit card fees to distributors under the condition that they would not charge patients higher fees when purchasing their primary product, Eylea.
2. Price Subsidization: The payments made to distributors are alleged to have subsidized the prices charged to customers using credit cards, thus, allowing for competitive pricing advantages in what is a sensitive market for retina practices.
3. Reported Sales Misrepresentation: As a result of the alleged actions, it is said that Regeneron artificially inflated reported sales figures for Eylea, leading to misleading positive portrayals of the company’s performance.
4. Violation of the False Claims Act: The failure to properly disclose these credit card fee payments has led to allegations of overstating Average Selling Price (ASP) reports to federal agencies, which constitute a violation of the False Claims Act.
5. Investor Misleading Statements: The public statements made by Regeneron concerning the company’s operations and expectations were allegedly based on these misrepresented figures, thereby misleading shareholders and the market.

Registration and Deadlines

Shareholders are urged not to delay in registering for participation in this class action lawsuit. The deadline to seek lead plaintiff status or to register your information is March 10, 2025. Interested shareholders can easily register by visiting the secure link provided by The Gross Law Firm.

Next Steps for Investors

Once registered, shareholders will receive updates and monitoring services to keep them informed throughout the duration of the lawsuit. This ensures that those participating are kept in the loop regarding any developments in the case. Importantly, there is no cost to shareholders for participation, making this a risk-free opportunity to potentially recover losses resulting from the alleged misconduct.

Why Choose The Gross Law Firm?

The Gross Law Firm stands out as a nationally recognized class action law firm dedicated to safeguarding investor rights. With a commitment to holding corporations accountable for their practices, the firm focuses on securing justice for investors impacted by fraud and deceptive business practices. They advocate for corporate responsibility and aim to recover losses for those affected by untrue or misleading statements made by companies.

Contact Information

For shareholders wishing to learn more or for those who want to begin the registration process, The Gross Law Firm can be reached through the following details:

• - Phone: (646) 453-8903
• - Email: info@grosslawfirm.com
• - Address: 15 West 38th Street, 12th Floor, New York, NY 10018

The legal landscape surrounding corporate transparency and investor rights has never been more critical. Shareholders of Regeneron Pharmaceuticals are encouraged to stay informed and act quickly as the implications of this lawsuit could be significant for affected investors.